Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report

• Үндсэн зохиолчид: Boney Joseph (Зохиогч), Nicolas A. Nunez (Зохиогч), Simon Kung (Зохиогч), Jennifer L. Vande Voort (Зохиогч), Vanessa K. Pazdernik (Зохиогч), Kathryn M. Schak (Зохиогч), Stacey M. Boehm (Зохиогч), Brooke Carpenter (Зохиогч), Emily K. Johnson (Зохиогч), Grigoriy Malyshev (Зохиогч), Nathan Smits (Зохиогч), Daniel O. Adewunmi (Зохиогч), Sarah K. Brown (Зохиогч), Balwinder Singh (Зохиогч)
• Формат: Ном
• Хэвлэсэн: MDPI AG, 2023-08-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Intravenous (IV) ketamine and FDA-approved intranasal (IN) esketamine are increasingly used for treatment-resistant depression (TRD). Preliminary studies have suggested a synergistic effect of ketamine and lamotrigine, although the data are inconclusive. Herein, we report the response to serial keta...